Reading ITGR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ITGR free→Reading ITGR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ITGR free→NYSEHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, while management's recent track record has been steady and capital-friendly. Earnings quality is neutral, and risk is elevated, with the sector backdrop presenting a headwind. Peer multiples imply a price about 13% above where it trades (it looks cheap on this basis); the read is fair. Key factors to watch include any potential guidance cuts from ITGR and the performance of sector bellwethers like ABT, SYK, and MDT. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $90.82. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $91 ITGR trades at 14× p/e, below its 23× p/e peer median. Our $104 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 13% below a flat-multiple fair value, below our forecast of about 8%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.34x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.54 → $1.38 (-10.3% / 30d). 0 raised, 8 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 60% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$115.
How much price usually moves either way.
On a bad day, this stock has moved -$294.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,851.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show how well the company is doing with money and operations.
Confirms one read:Earnings results show a positive trend in revenue or income compared to Q1 2026.
Confirms the other:Earnings results show a decline in revenue or income compared to Q1 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ITGR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Approval of Certain Compensation Matters In connection with a strategic review to maximize stockholder value that was previously announced by Integer Holdings Corporation (the “Company”), on May 18, 2026, the Compensation and Organization Committee (the “Compensation Committee”) of the Board of Directors of the Company (the “Board”) approved (or re…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ITGR Integer Holdings Corporation | Above typical Show detailsSector percentile: 75 of 100 | fair | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 93 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Board has initiated a strategic review to explore opportunities like a sale, merger, or strategic business combination.
Focus on maintaining stable operating income despite market headwinds and restructuring costs.
Enhance cash flow from operating activities to support strategic initiatives and financial stability.
Why it matters: The review could lead to actions that impact stockholder value. Investors need to know the outcomes.
Confirms:A press release will share news about actions or milestones from the strategic review.
Disproves:No updates or actions have been announced about the strategic review for a long time.
Why it matters: If organic sales growth stays steady, it shows the company can fix product issues.
Confirms:Q2 2026 organic sales growth reported at or above 1.3%.
Disproves:In Q2 2026, organic sales growth was below 1.3%.
Why it matters: Better cash flow helps the company invest and manage its debt well.
Confirms:Cash flow from operations in Q2 2026 exceeds $200 million.
Disproves:Cash flow from operations in Q2 2026 falls below $185 million.
Why it matters: Better cash flow is important for running operations and growth.
Confirms:Cash flow from operations is over $205 million in 2026.
Disproves:Cash flow from operations drops below $185 million in 2026.
Why it matters: Stable operating income shows that costs are managed well. This is important during product challenges.
Confirms:Q2 2026 operating income stays the same or goes up from Q1 2026.
Disproves:Q2 2026 operating income drops a lot compared to Q1 2026.
Why it matters: Updates on the strategic review could show ways to create value for shareholders.
Confirms:A clear deal or decision from the review will be announced.
Disproves:No updates or delays in the strategic review process.
Results of Operations and Financial Condition. On April 30, 2026, Integer Holdings Corporation (the “Company”) issued a press release announcing its results for its first quarter ended April 3, 2026. A copy of the release is furnished with this report as Exhibit 99.1 and is incorporated by reference into this
Regulation FD Disclosure. On April 30, 2026, the Company issued a press release announcing that the Company’s Board of Directors has initiated a strategic review to maximize stockholder value. A copy of the release is furnished as Exhibit 99.2 to this Current Report on Form 8-K. Additionally, the Company has updated its Earnings Conference Call slide presentation for its first quarter ended April 3, 2026, and will make it available on the Company’s website at www.integer.net, under “Investor…
Entry into a Material Definitive Agreement. On March 9, 2026 (the “Effective Date”), Integer Holdings Corporation (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) by and among the Company, Irenic Capital Management LP, a Delaware limited partnership, Irenic Capital Management GP LLC, a Delaware limited liability company, Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership, and Irenic Capital Evergreen Fund GP LLC, a Delaware limited…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.02(d) Pursuant to the Cooperation Agreement, the Board appointed the Cooperation Agreement Directors as members of the Board, at which time it also increased the size of the Board to 13, effective March 12, 2026. Further, the Board will include the Cooperation Agreement Directors as part of the Company’s slate of nominees for election to the…